WP
RCKT icon

Woodline Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Woodline Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Hold
641,222
– – 0.01% 827
2026
Q1 		$2.3M Buy
+641,222
New +$2.55M 0.01% 792
2025
Q3 		– Sell
-652,865
Closed -$1.6M – 1015
2025
Q2 		$1.6M Hold
652,865
– – 0.01% 755
2025
Q1 		$4.35M Buy
652,865
+444
+0.1% +$4.39K 0.03% 539
2024
Q4 		$8.2M Buy
652,421
+51,358
+9% +$773K 0.06% 390
2024
Q3 		$11.1M Buy
601,063
+39,097
+7% +$801K 0.09% 278
2024
Q2 		$12.1M Buy
+561,966
New +$12.9M 0.12% 228
2023
Q2 		– Sell
-326,605
Closed -$5.59M – 730
2023
Q1 		$5.59M Buy
326,605
+106,352
+48% +$2.08M 0.08% 276
2022
Q4 		$4.31M Buy
+220,253
New +$4.06M 0.06% 341
2022
Q2 		– Sell
-142,011
Closed -$2.25M – 871
2022
Q1 		$2.25M Buy
+142,011
New +$2.45M 0.04% 366

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Woodline Partners's RCKT Position: Q2 2026 in Review

Woodline Partners held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 641,222 shares worth $2.19M. The position accounts for 0.01% of the portfolio, ranked #827.

Woodline Partners first reported a position in RCKT in Q1 2022 and has held it in 10 quarters since. The position peaked at $12.1M in Q2 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Woodline Partners held 641,222 shares of Rocket Pharmaceuticals worth $2.19M as of Q2 2026.
  • Woodline Partners left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #827 holding.
  • Woodline Partners first reported a position in Rocket Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • Woodline Partners's Rocket Pharmaceuticals position peaked at $12.1M in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.